May 08, 2021
2 min watch
Save
VIDEO: Brolucizumab demonstrates drying effect in patients with DME
WAILEA, Hawaii — In this video from Hawaiian Eye, Rishi P. Singh, MD, discusses results from the KITE and KESTREL trials of brolucizumab vs. aflibercept in the treatment of diabetic macular edema.
The 52-week endpoint results, recently presented at the virtual Association for Research in Vision and Ophthalmology meeting, showed a higher proportion of patients with fluid resolution in the brolucizumab (Beovu, Novartis) arm than the aflibercept (Eylea, Regeneron) arm.